Trial Profile
A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Single-ascending Dose, First Time Into Man Study to Assess the Safety, Tolerability, and Pharmacokinetics (Part A) and an Open-label Assessment of the Effect of Food on the Pharmacokinetics (Part B) of Orally Administered AZD8418
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2016
Price :
$35
*
At a glance
- Drugs AZD 8418 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors AstraZeneca
- 16 May 2014 New trial record